Common questions about Thai FDA registration across pharmaceuticals, dietary supplements, and medical devices, answered in plain regulatory language.
Under Thai law, a foreign manufacturer cannot hold a Thai FDA marketing authorization unless it operates a licensed Thai establishment. A Local Authorized Representative is a Thai-licensed entity appointed to hold the marketing authorization on the foreign manufacturer's behalf. The LAR bears full legal responsibility for the product on the Thai market, including labeling compliance, post-marketing surveillance, variation submissions, and license renewal. Selecting the right LAR is one of the most consequential early decisions in any Thailand market entry, and the quality of that relationship directly affects how quickly and cleanly registration proceeds.
Timeline depends on the product type and registration category. For generic drugs, Thai FDA's published review target is 120 business days once a complete dossier is formally accepted; for new drugs, the target is 220 business days. End-to-end, from initial planning through approval, foreign manufacturers typically budget 12 months or more, accounting for local holder setup, import-for-registration permits, dossier preparation, and the review queue position at submission. For dietary supplements the process is generally shorter; for medical devices, classification determines whether notification or full registration applies, and each carries its own timeline.
Prior approval in a stringent regulatory authority jurisdiction is recognized by Thai FDA as positive evidence of safety and quality, but it does not create an automatic fast-track pathway for drug products. For pharmaceuticals, prior approval in a recognized stringent market may support eligibility for the Safety Monitoring Program (SMP), which is a conditional registration mechanism rather than an expedited full registration. For medical devices, Thai FDA accepts conformity assessment results from recognized bodies, including CE marking and US FDA clearance, as supporting evidence within the technical file, particularly for higher-risk device classes. The practical benefit is that your existing documentation substantially reduces the preparation work for a Thai-format submission, even where the regulatory pathway itself does not shorten.
The common foundation across product types is: a current GMP certificate from the competent authority of your country of manufacture, product technical specifications and quality documentation, safety and efficacy evidence in a Thai-accepted format (ACTD for drugs, technical file or CSDT for devices), Thai-language labeling, and a power of attorney authorizing your local holder to act on your behalf. For dietary supplements, the core package is an FDA Form 2 registration application with quality documentation, Thai labeling, and GMP evidence. Specific form numbers, fee schedules, and supporting-document checklists are confirmed at engagement, because Thai FDA updates these requirements and applicant guidance periodically.
A product registration (marketing authorization or product license) is Thai FDA's approval that a specific product may be sold in Thailand. An import license is a separate, consignment-specific authorization for each physical shipment entering the country. The two are distinct: a product license authorizes sale; an import license authorizes the individual consignment. Foreign manufacturers must hold a valid product license and also obtain an import license for each consignment through their licensed local holder or importer of record. The import license is product-specific and must be applied for before each shipment; it does not persist automatically across consignments.
Classification depends on the reference product and the date of its first Thai FDA approval. A product referencing a comparator first approved by Thai FDA after B.E. 2534 (1991) follows the new generic pathway, which requires a bioequivalence study or an approved waiver. A product containing a new chemical entity, a new biological entity, or introducing a new indication, new dosage form, or new route of administration files as a new drug, which carries the highest data burden and the longest review timeline. The B.E. 2534 (1991) cutoff is established by ministerial notification and is consistently applied in Thai regulatory practice as the dividing line between the two generic pathways.
ACTD stands for ASEAN Common Technical Dossier. Thailand, as an ASEAN member state, requires drug registration dossiers to follow this format rather than the ICH CTD format used in the EU, US, and other ICH markets. The ACTD has 4 Parts: Part I (administrative and product information, required in Thai), Part II (quality data, required in Thai), Part III (nonclinical data), and Part IV (clinical data). Parts III and IV are accepted in English. Thai FDA screens for ACTD format compliance before accepting a dossier for review; a submission that does not meet the format requirements will not advance to substantive review regardless of the quality of the data it contains.
Thailand is a Pharmaceutical Inspection Co-operation Scheme (PIC/S) member state. Thai FDA requires a current GMP certificate issued by the competent authority of the country of manufacture, and certificates from other PIC/S-member authorities (which include the European regulatory agencies, US FDA, TGA Australia, Health Canada, and others) are recognized. The certificate must be current at the time of dossier submission and must remain valid throughout the entire review period: an expired GMP certificate can halt a dossier that is already under review. For new drug applications, Thai FDA retains the right to conduct its own manufacturing site inspection independently of existing PIC/S certification.
The SMP is a conditional registration pathway for products that are approved and in commercial use in a recognized stringent regulatory authority jurisdiction but have limited post-marketing safety data from Thai or regional patient populations. SMP approval is time-limited and carries mandatory post-marketing safety reporting and pharmacovigilance obligations. The designation is reviewed at intervals; once sufficient local safety evidence is accumulated, it may be converted to full registration. SMP is not an expedited approval mechanism: it is a controlled pathway for managing residual uncertainty while allowing earlier market access under defined conditions, and the post-marketing obligations that attach to it are substantive.
Marketing Authorization Holder (MAH) and Local Authorized Representative (LAR) are terms sometimes used interchangeably in Thai pharmaceutical practice but carry distinct technical meanings. The MAH is the legal entity in whose name the marketing authorization is issued and who bears full regulatory and legal responsibility under the Drug Act. The LAR designation describes the local entity appointed to represent the foreign manufacturer in dealings with Thai FDA. In most foreign-manufacturer structures, a single Thai entity serves both roles: it holds the marketing authorization and manages all regulatory correspondence. The structure must be formally established through the applicable establishment licensing and power-of-attorney documentation before registration can proceed.
Thai FDA categorizes post-approval changes as major or minor variations. Major variations require a new application and full dossier review; examples include changes to the manufacturing site for the finished product, changes to the drug substance manufacturer, and new indications or new dosage forms. Minor variations require notification or a simplified review; examples include labeling updates, minor manufacturing process changes within approved parameters, and certain packaging changes. The classification of a specific proposed change must be confirmed against current Thai FDA variation guidelines before submission, as the boundary between major and minor can differ from EU or US categorizations of the same change.
Thailand regulates dietary supplements under the Food Act (B.E. 2522, 1979) administered by the Thai FDA's Food Division. A dietary supplement is a food product intended to supplement the normal diet with nutrients or other substances that have nutritional or physiological effects; it is not intended to treat, cure, or prevent disease. Typical categories include vitamins, minerals, herbal extracts, amino acids, and similar nutrients in concentrated form. The distinction between a dietary supplement, a functional food, and a drug is determined by the product's composition, the claims on the label, and its intended use, and that classification has material consequences for the registration pathway, permissible claims, and ongoing compliance obligations.
The Orr.7 is the import license issued under the Food Act for importing food products, including dietary supplements, into Thailand. It is product-specific and consignment-specific; it is not a standing import authorization that covers all future shipments. The license must be obtained through a Thai-licensed food importer (the local importer) before each consignment can clear Thai customs. Foreign manufacturers do not apply for Orr.7 directly; they operate through their licensed local importer, who holds the food establishment license issued by Thai FDA required to make the application.
Thai FDA requires dietary supplement manufacturers to meet Good Manufacturing Practice standards. For foreign manufacturers, Thai FDA accepts GMP certificates or audit documentation from recognized national authorities and frameworks, including certifications aligned with CODEX Alimentarius GMP guidelines or equivalent international standards. Internationally recognized certifications such as NSF or ISO 22000 support the GMP documentation package within the application, though the specific documents accepted and their format requirements are confirmed at the submission stage. GMP documentation is a core element of the FDA Form 2 registration application for imported supplements.
Health claims for dietary supplements in Thailand are regulated as a positive list: only claims that Thai FDA has pre-approved may appear on the label. Permissible claims are nutrient function claims (for example, "Calcium contributes to normal bone health") rather than therapeutic or disease-treatment claims. Unapproved claims, including disease-cure claims, comparative efficacy claims, and health benefit claims not on the approved list, are prohibited and can result in product recall, label amendment requirements, or removal of registration. The approved claim list is published by Thai FDA and is updated periodically; confirming permissible claims against the current list before finalizing label design is a required step in the registration process.
A novel food or novel ingredient is one that has no significant history of consumption in Thailand or that uses a new production process affecting its composition or biological availability. Thai FDA evaluates novel ingredients through a dedicated safety assessment process under the Food Act before the product may proceed to standard registration. The assessment draws on available safety data, international regulatory precedents (including EU novel food frameworks and US GRAS determinations), and estimated consumer exposure. Timelines for novel ingredient assessment are not fixed and depend on the completeness of the safety dossier submitted; manufacturers should plan for a pre-registration safety review phase as a distinct step in the market-entry schedule.
The Kho Or permit is the food advertisement approval required under Food Act (B.E. 2522, 1979) Section 41 before any advertisement for a dietary supplement may be broadcast or published in Thailand. The requirement applies to television, radio, print, digital, and social media advertising that makes health or nutritional claims about a regulated food product. The application is submitted to Thai FDA's Food Division and requires submission of the proposed advertising content for review before publication or broadcast. The permit is issued per product and per advertising campaign; operating a supplement advertising campaign without a valid Kho Or permit is a regulatory violation carrying defined penalties.
Under the Medical Device Act B.E. 2551 (2008), 2019) and its implementing ministerial notifications, Thai FDA classifies devices into 4 risk classes through the AMDD framework. Class 1 devices are the lowest risk and include basic instruments and simple non-sterile equipment; they require notification to Thai FDA before commercial sale, not full registration. Class 2 devices require registration with a simplified technical dossier. Class 3 and Class 4 devices are higher-risk products including sterile single-use devices, active implantable devices, and certain in vitro diagnostics; they require full technical file submission and substantive Thai FDA review. The classification of a specific device determines the entire regulatory pathway, the applicable fee schedule, and the expected timeline.
Thai law requires a Thai-licensed establishment to hold the device license for any medical device sold or imported into Thailand. This entity, the local license holder, must hold a valid establishment license issued by Thai FDA's AMDD covering the relevant activity (importation, distribution, or manufacturing). The local license holder is responsible for all Thai FDA correspondence, post-market surveillance reporting, recall management, and maintaining the accuracy of the registered product information. Foreign manufacturers cannot directly hold a Thai device license; appointing a qualified local license holder is a prerequisite before any product-level registration or notification application can be filed.
A CSDT (Common Submission Dossier Template) is the ASEAN-format medical device registration dossier, structured according to an agreed ASEAN template with defined sections for administrative data, device description, summary technical documentation, labeling, and post-market surveillance data. A technical file is a more general term for the compilation of technical documentation required for device registration; in EU practice this refers specifically to the documentation package supporting CE marking. Thai FDA accepts both the CSDT format and technical documentation prepared to international standards for Class 3 and Class 4 device applications. Manufacturers experienced with the EU Technical File or US 510(k) documentation will find the underlying content requirements broadly familiar, though the CSDT structure, section numbering, and language requirements are distinct.
The Medical Device Act B.E. 2551 (2008), 2019) and its implementing ministerial notifications issued under B.E. 2568 (2025) establish mandatory labeling content for medical devices sold in Thailand. Labels must be in the Thai language, or bilingual Thai and English, and must include: the device name, the manufacturer's name and address, the local license holder's name and Thai FDA registration or notification number, the intended use, instructions for use, applicable safety warnings, storage conditions where relevant, and the batch or lot number with expiry date for sterile or time-sensitive products. Approved label content forms part of the registered product record; any change to that content after registration requires a variation submission to Thai FDA before the amended label may be used commercially.